Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | CCR3 | P51677 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16812724 | 0.94 | SMO (0.52) | SMORETSSTR5SLC6A5DRD4 | |
| SCHEMBL18286594 | 0.92 | SMO (0.56) | SMOSSTR5SLC6A5DRD4MCHR1 | |
| SCHEMBL16812734 | 0.92 | SMO (0.56) | SMORETSLC6A5DRD4CCR3 | |
| SCHEMBL16812718 | 0.92 | SMO (0.55) | SMOSLC6A5DRD4CCR3MCHR1 | |
| SCHEMBL16812726 | 0.91 | SMO (0.49) | SMORETSSTR5HPGDS | |
| SCHEMBL16812572 | 0.91 | SMO (0.71) | SMORETSSTR5SLC6A5DRD4 | |
| SCHEMBL16811807 | 0.89 | SMO (0.64) | SMORETDRD4CCR3MCHR1 | |
| SCHEMBL16812735 | 0.88 | SMO (0.52) | SMORETSSTR5SLC6A5DRD4 | |
| SCHEMBL18286515 | 0.87 | SMO (0.62) | SMOSSTR5DRD4CCR3MCHR1 | |
| SCHEMBL16812720 | 0.86 | SMO (0.52) | SMORETSSTR5SLC6A5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166509-A1 | SMOOTHENED MODULATORS AND METHODS OF USE THEREOF | UNIV DUKE (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166509-A1 | SMOOTHENED MODULATORS AND METHODS OF USE THEREOF | SMO, SHH, GLI1 | SMO 1/4885RET 439/4885SSTR5 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.